ONCAlert | 2018 ASCO Annual Meeting

Combining Immunotherapy With Antiangiogenesis in RCC

Toni Choueiri, MD
Published Online:1:20 PM, Fri March 23, 2018

Toni Choueiri, MD: So, there’s a recent trial that reported on the activity of a VEGF inhibitor, well-tolerated bevacizumab, and a PD-L1 inhibitor atezolizumab in metastatic RCC, a phase III trial against sunitinib. Primary endpoint was investigator-assessed progression-free survival in the PD-L1–positive population, and this was met. The regimen was extremely well tolerated, though it’s early to add the regimen and have for it a certain place for many reasons. First, the overall survival is still not mature enough. But this is an interesting and evolving story with a well-tolerated regimen.

The other important consideration with this regimen is that the independent review of the scan didn’t show superiority of the combination over sunitinib. So, I think it’s too early to comment on that regimen, but certainly the follow-ups will be very important on this trial.

Transcript edited for clarity.

Toni Choueiri, MD: So, there’s a recent trial that reported on the activity of a VEGF inhibitor, well-tolerated bevacizumab, and a PD-L1 inhibitor atezolizumab in metastatic RCC, a phase III trial against sunitinib. Primary endpoint was investigator-assessed progression-free survival in the PD-L1–positive population, and this was met. The regimen was extremely well tolerated, though it’s early to add the regimen and have for it a certain place for many reasons. First, the overall survival is still not mature enough. But this is an interesting and evolving story with a well-tolerated regimen.

The other important consideration with this regimen is that the independent review of the scan didn’t show superiority of the combination over sunitinib. So, I think it’s too early to comment on that regimen, but certainly the follow-ups will be very important on this trial.

Transcript edited for clarity.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.